Evidence map›Paper›PMID 31708732›Full record

ArticleFrontiers in neuroscience2019

Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma.

Qi Chen, Min Zhao, Chengliang Yin, Shiyu Feng, Jian Hu, Qiang Zhang, Xiaodong Ma, Wanguo Xue, Jinlong Shi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Qi ChenNational Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
Min ZhaoNational Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
Chengliang YinNational Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
Shiyu FengDepartment of Neurosurgery, Chinese PLA General Hospital, Beijing, China.
Jian HuDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Qiang ZhangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Xiaodong MaDepartment of Neurosurgery, Chinese PLA General Hospital, Beijing, China.
Wanguo XueNational Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
Jinlong ShiNational Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS:

Indexed as

biomarkerglioblastomajoint-scoremethylationprognostic evaluation

Identifiers

PMID31708732
PMCPMC6823878
OpenAlexW2981960633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.